Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $5.00 | Outperform → In-line | Evercore ISI |
| 5/28/2025 | Overweight → Neutral | Analyst | |
| 5/28/2025 | $2.00 | Neutral → Sell | Goldman |
| 5/28/2025 | $8.00 | Outperform → Market Perform | Leerink Partners |
| 5/28/2025 | $2.50 | Buy → Hold | Jefferies |
| 5/28/2025 | $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/27/2025 | Buy → Hold | TD Cowen | |
| 5/27/2025 | Buy → Hold | Needham |
Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00
Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral
Goldman downgraded Rocket Pharmaceuticals from Neutral to Sell and set a new price target of $2.00
NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl
Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c
RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up RP-A601 promoted increased protein expression and desmosomal localization of Plakophilin-2 (PKP2), Desmocollin-2, and Cadherin-2 in all three patients Improvement or stabilization observed in arrhythmia burden, heart function, and quality of life in all patients No further dose escalation planned Investor webinar to be held later today at 4:30 p.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,